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Today, the vast majority of medicinal products are prepared industrially. However, 
medicinal products manufactured by the pharmaceutical industry are not always 
authorised, or available, to cover the special needs of individual patients. Pharma-
ceutical companies, and indeed, pharmacies themselves are certainly involved in 
individual health care. But, in practice, pharmacists are confronted with the special 
needs of patients for which no licensed industrial product is available on the mar-
ket. However, society expects the pharmacist to dispense a pharmacy preparation 
which can meet the special medical needs of individual patients. There are many 
examples of special patient needs which can be treated with pharmacy prepara-
tions, such as the special needs of children and the elderly.  
The regulation of the preparation of medicinal products was started on a European 
level in 1965, three years after the thalidomide tragedy in which thousands of in-
fants of mothers who had used the drug during pregnancy were born with mal-
formed limbs. Arms and legs were either not developed or presented themselves 
as stumps. Many of these infants did not survive. This tragedy led to the develop-
ment of more structured drug regulations in order to prevent this from happening 
again. Since 1965, the European regulation has been built upon two important 
pillars:  
- Product design quality 
Marketing authorisation was now required which has to be issued for each me-
dicinal product by the competent regulatory authority before the product is 
placed on the market.  
- Production quality 
The manufacturer must obtain a manufacturing licence issued by the compe-
tent authority. Compliance with Good Manufacturing Practice is obligatory for 
manufacturers of medicinal products.  
There are some exceptions to the European regulation, such as specific pharmacy 
preparations and medicinal products to meet special medical needs. It is legal for 
pharmacists to prepare any medicinal product in the pharmacy as long as it falls 
under the exceptions to the European regulation. If these exceptions are applica-
ble, then any legislation and standards relating to the quality and safety of phar-
macy preparations are, in principle, set at the national level.  
We have shown in this thesis that today, not every pharmacist in Europe prepares 
medicines. Instead, there are preparing and distributing pharmacies (PDPs) in 
many countries to which the pharmacist can outsource pharmacy preparation. 
These PDPs prepare medicinal products in their pharmacy and distribute these 
products to dispensing pharmacies.  
Some of these PDPs have developed into companies which prepare medicinal 
products on a large scale, while retaining their formal status as a pharmacy. Prepa-
ration on a large scale, however, increases the risks to patient care, for example in 
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the case of defects in the quality of the product. To contain these risks, stringent 
quality and safety standards have to be put in place. We have shown that there is a 
lot of variation in the quality and safety standards applied in Europe. This varia-
tion, includes standards for PDPs. This is, for example, the case, when regarding 
the requirements for production quality. Moreover, standards for product design 
quality were, apparently, missing in most of the countries.  
In addition, we have shown that, based on case law in 2015, there are few legal 
opportunities for pharmacy preparations and individual health care. The European 
Court of Justice (ECJ) has provided a strict interpretation of the exceptions to Eu-
ropean regulation for pharmacy preparations. This is laid out in Directive 
2001/83/EC, in particular with regard to the magistral formulae and the officinal 
formulae. European regulation applies to all medicinal products prepared indus-
trially or manufactured by a method involving an industrial process (hereafter: 
industrial and industrial process medicines, IPMs). This is irrespective of whether 
these products are made by a private company or in a pharmacy. Therefore, the 
regulation is mandatory for all people and companies preparing IPMs. The excep-
tions to European regulation apply to small-scale pharmacy preparation, for ex-
ample the magistral and officinal formulae. Since many pharmacies have become 
dispensing pharmacies which do not prepare medicinal products, this option of 
small-scale preparation has been replaced in many countries by preparation 
through PDPs. These now make medicinal products to satisfy the medical needs of 
the patients of these dispensing pharmacies. However, the exceptions to European 
regulation are not applicable to PDPs. PDPs making unlicensed medicines to meet 
the special medical needs of individual patients belonging to pharmacies, and who 
do not prepare their own medicinal products, are not recognised as an exception to 
European regulation. Consequently, this status of the PDPs poses a problem to the 
individual health care of these patients.  
We have shown that many European countries have attempted to find national 
solutions for PDPs in order to permit individual health care where needed and at 
the same time to ensure that medicinal products are safe, effective and of high 
quality. We have shown that, in the Netherlands, the measures taken by the au-
thorities regarding the quality and safety standards are generally accepted and 
followed by the PDPs. This Dutch regulation requires that pharmacy preparations 
are only permitted if there is a favourable pharmacotherapeutic rationale and if no 
licensed pharmacotherapeutical alternative is available on the market. In addition, 
a product dossier should be available for all products to ensure the product design 
quality and compliance with Good Manufacturing Practice (GMP) is required to 
guarantee the production quality. The different national solutions could form a 
basis for a reform of European regulation.  
We have shown that good progress has been made with the implementation of 
Resolution CM/ResAP(2011)1. This Resolution was confirmed again in 2016. 1 
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This means that the harmonisation of quality and safety standards for pharmacy 
preparations has made good progress in Europe. With regard to production quali-
ty, GMP is required in most of the countries for high-risk pharmacy preparations. 
For PDPs, for example, both the requirements of GMP and that for complying with 
good distribution practices (GDP) are followed in most countries. We have also 
shown that, in relation to the product design quality, the concept of product dossi-
ers has either been implemented or implementation is planned for most countries. 
We have also shown that there is room for improvement in other areas, such as the 
recommendation included in the Resolution to consider the requirement of a mar-
keting authorisation for specific pharmacy preparations in specific cases.  
We conclude that few, or no, quality and safety requirements have been laid down 
for preparations in clinical areas in health care establishments. We investigated the 
high risks for patients associated with the reconstitution of parenteral medicines 
and the immediate harm this can cause to patients. This is, in particular, the case in 
health care establishments where aseptic preparations are carried out in hospital 
pharmacies as well as in clinical areas. We defined, in this study, the options for 
quality and safety standards in relation to the patient risks which were detected. 
These were in order to ameliorate the process for aseptic preparations in health 
care establishments for the benefit of the patient. These standards include, for 
example, the nomination of a designated person in the health care establishment, 
the laying down of minimum requirements for quality standards in clinical areas to 
be included in a quality system, and the application of a risk assessment approach 
as a basis for a decision about which products can be reconstituted safely, in which 
locations in the health care establishment, and under which conditions.  
In our thesis, we have shown that the harmonisation of quality and safety stand-
ards in Europe, for all pharmacy preparations, is making good progress. However, 
now we face another problem, as we have shown in Chapter 4. This is that the legal 
opportunities for pharmacy preparations have diminished over the years thus 
hindering the further implementation of the harmonised quality and safety stand-
ards of 2011. 1  
We have investigated European legislation for pharmacy preparations and its rela-
tionship to the European quality and safety standards of 2011.1  
European regulation, more specifically Directive 2001/83/EC, is outdated as far as 
pharmacy preparations are concerned and from the perspective of the patient its 
reform is needed urgently.  
Small-scale preparation of medicinal products is addressed in European regulation 
and permitted under the competencies of the national authorities. However, this 
does not offer opportunities for the patient with special medical needs. Today, 
many pharmacies in Europe have stopped preparing products and have out-
sourced pharmacy preparations to PDPs which make preparations on a larger 
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scale. Yet, European regulation was created at a time when every pharmacists 
made medicinal products for his or her own patients and when large-scale phar-
macy preparation did not exist.  
The option that pharmacies which do not prepare medicinal products should make 
use of the services of PDPs would be one possible means to benefit the patient with 
special needs. However, PDPs may exist in many European countries but they are 
not addressed in European regulation. It is shown that according to recent case law 
of the European Court of Justice, the exceptions from European regulation are not 
applicable to PDPs. In particular the Abcur case has caused a lot of uncertainty 
among pharmacists in Europe. This uncertainty is based upon concerns that there 
may no longer be a legal option for PDPs to make preparations on a larger scale – 
that is aimed at serving the special medical needs of patients. PDPs have to comply 
with Directive 2001/83/EC and the exceptions for pharmacy preparations do not 
apply to them. 
Our study shows that many European countries try to find national solutions 
which allow pharmacotherapy to be tailored to the needs of individual patients on 
the one hand and which ensure that medicines are safe, effective and of high quali-
ty on the other. It has been shown that Dutch standards for PDPs have been ac-
cepted and that PDPs are capable of complying with adequate quality and safety 
standards.  
The harmonised quality and safety standards for pharmacy preparations of 20111 
and the different national solutions could serve as a basis for a change in European 
regulation which is urgently needed from the perspective of the patient.  
In the specific area of reconstitution in health care establishments, our research 
shows that there is little or no regulation in this area in most of the member states 
of the Council of Europe. The risks associated with the aseptic preparation of par-
enteral medicinal products in health care establishments, and the options for re-
ducing the patient risks by setting up regulation for Good Reconstitution Practices, 
have been studied. The 2016 quality and safety standards for good reconstitution 
practices 2 reduce the risks associated with the reconstitution of parenteral medi-
cines and thus offers an opportunity for improvements in patient safety. 
Research calls for more research.  
Further research is needed to show how the implementation of the good reconsti-
tution practices of 2016 will develop over time in the different Council of Europe 
member states.  
The implications for further research in the area of pharmacy preparation are also 
included in this thesis. This research should be aimed at making the best use of the 
harmonised quality and safety standards and the different national solutions for 
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the required change in European regulation. Pharmacy preparations aimed at sat-
isfying the medical needs of individual patients need to have a solid legal position 
in Europe and medicines must be safe, effective and of high quality. This could be 
achieved by means by setting standards for production quality and product design 
quality. Future research in the area of pharmacy preparations in Europe should 
adopt a structured approach in order to coordinate all the efforts aimed at serving 
the interests of the patient. 
There is an urgent need for future research into the areas of pharmacy preparation 
and preparations in health care establishments. It is essential to make this 
knowledge available, because society expects the pharmacist to dispense a phar-
macy preparation dedicated to the special medical needs of individual patients. 
Based on his or her expertise in pharmacy preparation, the pharmacist has oppor-
tunities to extend this role to the benefit of the patient in health care establish-
ments.  
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